Huw Jones, a 33-year-old father from Llanuwchllyn in north Wales, succumbed to an aggressive form of bile duct cancer known as cholangiocarcinoma in February. His diagnosis came as a devastating shock, occurring just a day before his partner's 20-week pregnancy scan. Despite his battle with stage 4 cancer, Huw became a vocal advocate for zanidatamab, a new targeted treatment he believed could significantly improve the quality of life for patients suffering from the same condition. In his plea for the drug's approval, he emphasizes the hope it brings for a 'normal life' for those diagnosed with these aggressive cancer types.

Following Huw’s passing, his family has taken up the campaign, calling on health officials to reconsider the initial rejection of zanidatamab by Nice, the NHS’s spending watchdog. The charity AMMF, which focuses on cholangiocarcinoma, has reported that Nice is scheduled to meet in March to reassess the treatment's evidence for NHS availability. The family hopes that by shining light on Huw's story and the potential impact of zanidatamab, they can influence a positive decision from health officials, thus preventing other families from experiencing similar loss.

This case highlights the urgent need for access to innovative cancer treatments and the emotional toll such illnesses take on families. The rejection of novel therapies, often rooted in financial evaluations rather than the dire needs of patients, underscores the broader challenges within the healthcare system regarding timely access to advancements in cancer care. As discussions around zanidatamab continue, the family's advocacy aims not only to honor Huw's memory but also to forge a path for future patients who might benefit from this treatment.